STOCK TITAN

Theratechnologies Inc. - THTX STOCK NEWS

Welcome to our dedicated news page for Theratechnologies (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theratechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theratechnologies's position in the market.

Rhea-AI Summary
Theratechnologies Inc. announces the presentation of two posters at the AACR Annual Meeting 2024, showcasing the potential of their SORT1+ Technology™ platform for treating colorectal cancers. The studies demonstrate the effectiveness of sudocetaxel zendusortide (TH1902) in activating anti-PD-L1 immunotherapy tumor cell killing and introduce new camptothecin-peptide conjugates for SORT1+ colorectal cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
Rhea-AI Summary
Theratechnologies Inc. announced a shift towards a commercial focus by phasing down preclinical oncology research activities to prioritize the Phase 1 clinical trial of sudocetaxel zendusortide. The company aims to attract an oncology R&D partner leveraging its SORT1+ Technology platform. Theratechnologies also shared preclinical data at the AACR annual meeting and initiated the next cohort of patients in the Phase 1 trial. The restructuring will incur cash and non-cash charges to optimize the organizational cost structure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Summary
Theratechnologies Inc. appoints Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and Audit Committee. Mr. Zwick brings extensive experience in the biotech and pharmaceutical industry, global finance, and corporate strategy to guide Theratechnologies towards profitability and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
management
Rhea-AI Summary
Theratechnologies Inc. announces progression to next dose level in Phase 1 clinical trial for sudocetaxel zendusortide in advanced ovarian cancer patients, with positive safety outcomes and enrollment of first patient in second cohort.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
clinical trial
-
Rhea-AI Summary
Theratechnologies Inc. announces the resignation of Mr. Alain Trudeau from the Board of Directors and the Audit Committee. The Company plans to appoint a new independent director to ensure compliance with securities regulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
management
-
Rhea-AI Summary
Theratechnologies receives a refusal to file letter from the FDA for Trogarzo® IM administration, impacting their supplemental Biologics License Application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
Rhea-AI Summary
Theratechnologies Inc. reported a positive Adjusted EBITDA for Q4 2023, doubling from Q3 to $5 million, with a net loss of $2.8 million. The company achieved record quarterly revenue of $23.5 million and annual revenue of $81.8 million. Phase 1 trial for sudocetaxel zendusortide in ovarian cancer reached a milestone. Guidance for 2024 forecasts $87-90 million in revenue and $13-15 million EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
earnings
-
Rhea-AI Summary
Theratechnologies Inc. announces preclinical research results demonstrating the potential of sudocetaxel zendusortide in activating immune defense mechanisms and enhancing anti-PD-L1 immune-mediated tumor cell killing in triple-negative breast cancer. The publication highlights the superior tumor growth inhibition and immune cell infiltration compared to docetaxel in a murine tumor model, suggesting new avenues for combining immunotherapy with sudocetaxel zendusortide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
Rhea-AI Summary
Theratechnologies Inc. completes enrollment of the first six participants in Part 3 of Phase 1 clinical trial for TH1902 in advanced ovarian cancer patients, marking a significant milestone for the company's oncology development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
clinical trial
Rhea-AI Summary
Theratechnologies Inc. will report financial results and provide a business update for its fiscal 2023. They will also address the Complete Response Letter issued by the U.S. FDA for the F8 formulation of tesamorelin. The call will be hosted by Mr. Paul Lévesque, President and CEO, and other members of the management team. Participants are encouraged to join the call at least ten minutes in advance to secure access. Webcast and replay information is available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
earnings
Theratechnologies Inc.

Nasdaq:THTX

THTX Rankings

THTX Stock Data

67.27M
34.14M
6.29%
50.89%
0.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.